Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Efinaconazole Topical Solution, 10%".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Efinaconazole Topical Solution, 10%".